Immune Thrombocytopenia interventions: Difference between revisions
Homa Najafi (talk | contribs) Created page with "__NOTOC__ {{Adrenal insufficiency}} {{CMG}}; {{AE}} ==Overview== There are no recommended therapeutic interventions for the management of [disease name]. OR [name of inter..." |
Homa Najafi (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Immune Thrombocytopenia}} | ||
{{CMG}}; {{AE}} | |||
{{CMG}}; {{AE}} {{Maryam}} | |||
==Overview== | ==Overview== |
Latest revision as of 21:40, 18 January 2021
Immune Thrombocytopenia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Immune Thrombocytopenia interventions On the Web |
American Roentgen Ray Society Images of Immune Thrombocytopenia interventions |
Risk calculators and risk factors for Immune Thrombocytopenia interventions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Barkhordarian, M.D.[2]
Overview
There are no recommended therapeutic interventions for the management of [disease name].
OR
[name of intervention] is not the first-line treatment option for patients with [disease name]. [name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
OR
The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
OR
The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.
OR
[Name of intervention] is the mainstay of treatment for [disease or malignancy].
Indications
The mainstay of treatment for TT is medical therapy.